Please login to the form below
rheumatoid arthritis
This page shows the latest rheumatoid arthritis news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly to make bebtelovimab commercially available to US states from August
A trial led by The University of Oxford also demonstrated that baricitinib, an anti-inflammatory treatment usually used to treat rheumatoid arthritis, improved survival rate when given to patients who have
Latest news
-
Sandoz’s biosimilar medicine application accepted by FDA
adalimumab). The latest application comprises all indications covered by the reference medicine, including Crohn’s disease, plaque psoriasis, ulcerative colitis, rheumatoid arthritis and uveitis.
-
Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
A trial led by The University of Oxford also demonstrated that baricitinib, an anti-inflammatory treatment usually used to treat rheumatoid arthritis, improved survival rate when given to patients who have
-
Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis
Rheumatoid arthritis is a long-term condition that causes painful swelling and stiffness in the joints. ... Amgen’s Riabni (rituximab-arrx), in combination with methotrexate, has been approved by the US Food and Drug Administration (FDA) for adults
-
AbbVie’s Rinvoq accepted by SMC for atopic dermatitis
The SMC has now approved Rinvoq for the treatment of psoriatic arthritis, atopic dermatitis and rheumatoid arthritis for people living in Scotland.
-
Study provides new insights into Alzheimer's disease
Treatments that restrict TNF are already widely used to treat inflammatory diseases, including Crohn’s disease, rheumatoid arthritis and psoriasis.
More from news
Approximately 58 fully matching, plus 462 partially matching documents found.
Latest Intelligence
-
Setting up for success in a post-Brexit, post-pandemic Britain
and Rheumatoid Arthritis (RA). ... people with moderate as well as severe rheumatoid arthritis – aiming to avoid irreversible damage as early as possible.
-
The US celebrates five years of biosimilars on the market – a look to the past, present and future
chronic diseases such as rheumatoid arthritis.
-
NICE – but not enough
to severe rheumatoid arthritis.
-
AI: the smart money is on the smart thinking
Take, for example, the case of baricitinib, originally an Eli Lilly rheumatoid arthritis drug, now repurposed as a promising treatment for COVID-19.
-
Cortellis Drugs to Watch in 2020 report
Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... of the JAK family of kinases leads to an aberrant production
More from intelligence
Approximately 0 fully matching, plus 43 partially matching documents found.
Latest appointments
-
Portland Health appoints Jamie Hewitt as an account director
He joins the firm from the National Rheumatoid Arthritis Society, where he was its head of government affairs, leading the policy and public affairs functions. ... During his time at the National Rheumatoid Arthritis Society, Hewitt ran UK campaigns to
-
Liberation Unlimited promotes Vicky Smith
oncology, rheumatoid arthritis and eye health.
-
Galapagos appoints Bart Filius as chief financial officer
His vast experience in big pharma and his sharp strategic view will help us bring Galapagos to the next level, as we prepare to have our rheumatoid arthritis molecule GLPG0634 enter
-
TiGenix appoints Dr Marie Paule Richard
In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is
-
Liberation promotes Danielle Smith to account director
Meanwhile, Vicky joined Liberation last year and in her new role will continue to work across a range of therapeutic areas including men's health, rheumatoid arthritis and eye health.
More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
What does the future hold for clinical trial recruitment?
For example, new commonalities have been discovered between Type 1 diabetes, lupus, multiple sclerosis and rheumatoid arthritis, suggesting that drugs already in use to treat one autoimmune disease could be equally
-
Covid-19: how is it affecting prescribing patterns?
In this article, we will examine three key disease areas: COPD, rheumatoid arthritis and multiple sclerosis to determine which drug types have been the winners and losers in terms of usage ... Rheumatoid arthritis. Rheumatoid arthritis has seen a
-
The other side of … rheumatoid arthritis
The other side of … rheumatoid arthritis. “I harassed my GP enough to get it caught early”. ... Meet Georgie. At age 26, Georgie was diagnosed with rheumatoid arthritis, an autoimmune inflammatory condition that affects up to 1% of the population
-
Lucid Group reaches the finals of the PM360 2020 Trailblazer Initiative Awards
Lucid Group has been named as a finalist in the PM360 2020 Trailblazer Initiative Awards in the HCP Education category, for the program LiBRA 2019: Looking beyond the joint in rheumatoid ... arthritis (RA): Is there a missing link in RA management?
-
Lucid Group scoop a win and a high commendation at Communiqué 2020
Its programme – ‘LiBRA 2019: Looking beyond the joint in rheumatoid arthritis (RA): Is there a missing link in RA management?’ – won the category, with a high commendation going to ‘CLEAR HORIZONS – ... We were thrilled that our work in both
More from PMHub
Approximately 9 fully matching, plus 20 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- WHO releases interim statement on COVID-19 vaccination for children and adolescents
- Novartis reports death of two patients treated with Zolgensma
- The impact of COVID-19 on the fight against AMR
- NHS bowel cancer checks reach record-high following death of Dame Deborah James
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- Achieving communication excellence by targeting the right channel at the right time
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Novartis reports death of two patients treated with Zolgensma
- Pfizer, Mylan move ahead with generics merger and spin-out
- WHO, UNICEF and UNAIDS launch global alliance to end AIDS in children by 2030
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
